Nevertheless, there are different caveats regarding the use of CAR T-cells targeting BCMA, for example, the relevance of the heterogeneous BCMA expression on myeloma cells, the impact of sBCMA on the effectiveness of the therapy, and the relapses observed during the follow-up of most patients. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.